Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Bokemeyer, Carsten  [Clear All Filters]
Journal Article
Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023.
Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, et al. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 2020;135:1-7.
Ghandili S, Weisel KC, Bokemeyer C, Leypoldt LBeatrice. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. Oncol Res Treat. 2021:1-8.
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, et al. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget. 2015;6(8):6341-6358.
Schrage T, Görlach M, Betz CStephan, Bokemeyer C, Kröger N, Mueller V, Petersen C, Krüll A, Schulz H, Bleich C. Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study. JMIR Res Protoc. 2020;9(7):e17854.
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Kühling-Thees R, Ehm P, et al. Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts anti-leukemic effects. Clin Cancer Res. 2015.
Berger LArne, Bokemeyer C, Lorch A, Hentrich M, Kopp H-G, Gauler TChristoph, Beyer J, de Wit M, Mayer F, Boehlke I, et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol. 2014.
Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzelbecker J, Ruf C, Winter C, Zengerling F, et al. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group. World J Urol. 2022.
Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014;20(4):899-907.
Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Wiesch JSchulze Zu, Ding Y, Qi M, Hell L, et al. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells . Front Immunol. 2023;14:1250258.
Tintelnot J, Xu Y, Lesker TR, Schönlein M, Konczalla L, Giannou AD, Pelczar P, Kylies D, Puelles VG, Bielecka AA, et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature. 2023.
Seidel C, Paulsen F-O, Nestler T, Cathomas R, Hentrich M, Paffenholz P, Bokemeyer C, Heidenreich A, Nettersheim D, Bremmer F. Molecular and histopathological characterization of seminoma patients with highly elevated human chorionic gonadotropin levels in the serum. Virchows Arch. 2023.
Klement P, Fiedler W, Gabdoulline R, Dallmann L-K, Wienecke CPhiline, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, et al. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. Ann Hematol. 2022.
Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel KC, Bokemeyer C, Janjetovic S. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. Oncol Res Treat. 2021:1-6.
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu TVinh, Beitzen-Heineke A, Vargas-Delgado MElena, Pantel K, Bokemeyer C, et al. Regulation of bone homeostasis by MERTK and TYRO3. Nat Commun. 2022;13(1):7689.
Dyshlovoy SA, Hauschild J, Venz S, Krisp C, Kolbe K, Zapf S, Heinemann S, Fita KD, Shubina LK, Makarieva TN, et al. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models. Mol Pharm. 2023.
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuk F. Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. Anticancer Res. 2014;34(4):1779-84.